Original Article

Appropriateness of Proton Pump Inhibitor Use in Hospitalized Patients: A Cross Sectional Study in a Tertiary Care Hospital in North India


Background: Proton Pump Inhibitors (PPIs) are often prescribed inappropriately among hospitalized patients and same is often continued even after their discharge from the hospital. The inappropriate use of PPIs leads to an increased risk of adverse effects, drug interaction, and unnecessary hospital expenditure for such patients. Aim of this study was to determine the appropriateness of PPIs use among hospitalized patients. Methods: A cross sectional observational study was conducted on hospitalized patients in a tertiary care hospital in Northern India. The clinical records of adult patients hospitalized during April- May 2022 were assessed for the prescribing pattern and appropriateness of PPI use as per the National Institute of Health and Care Excellence (NICE) guidelines. Results: A total of 192 patient’s records were included in this study with the mean age 57 years and 61% of the study participants were males. Overall, 72% (138) of the study participants were prescribed PPIs by intravenous route and only in 28% (54) cases an oral route was preferred. Pantoprazole was the most commonly prescribed PPI in 112 (58%) patients and it was administered by intravenous route among 87 patients (78%) and by oral route in 25 (22%) patients. PPI use was appropriate in 54% of the cases and they were most commonly prescribed for ulcer prophylaxis. This study identified higher use of PPIs was seen in low risk patients for longer duration than indicated. Conclusion: PPIs are being prescribed inappropriately among hospitalized patient unrelated to their widely accepted clinical indications and are often continued unnecessarily once patient is discharged. These results suggest the need of regular audits on use of PPIs clubbed with educational initiatives to promote rational use of PPIs among hospitalized patients.

1. Ren D, Gurney E, Hornecker J. Appropriate use and stewardship of proton-pump inhibitors. US Pharm. 2019;44(12):25-31.
2. Gamelas V, Salvado V, Dias L. Prescription Pattern of Proton Pump Inhibitors at Hospital Admission and Discharge. GE Port J Gastroenterol. 2019;26(2):114-120.
3. Rückert-Eheberg IM, Nolde M, Ahn N, et al. Who gets prescriptions for proton pump inhibitors and why? A drug-utilization study with claims data in Bavaria, Germany, 2010-2018. Eur J ClinPharmacol. 2022;78(4):657-667.
4. Kazberuk M, Brzósko S, Hryszko T, Naumnik B. Overuse of proton pump inhibitors and its consequences. PostepyHig Med Dosw (Online). 2016;70:1112-1116.
5. Al-Dosari BS, Binafeef BM, Alsolami SA. Prescribing pattern of proton pump inhibitors among patients admitted to medical ward at King Abdulaziz University Hospital, Jeddah, Saudi Arabia: A retrospective study. Saudi Med J. 2021;42(12):1313-1319.
6. Mohzari YA, Alsaegh A, BasheeruddinAsdaq SM, Al Shanawani SN, Albraiki AA, Bagalb A. The Pattern of Intravenous Proton-Pump Inhibitor Utilization at an Academic Medical Center in Riyadh, Saudi Arabia. J Res Pharm Pract. 2020;9(3):151-154.
7. Kinoshita Y, Ishimura N, Ishihara S. Advantages and disadvantages of long-term proton pump inhibitor use. J Neurogastroenterol Motil. 2018;24:182-96.
8. Lenoir C, El Biali M, Luthy C, et al. Snapshot of proton pump inhibitors prescriptions in a tertiary care hospital in Switzerland: less is more?. Int J Clin Pharm. 2019;41: 1634–41.
9. Verma N, Tayal V, Roy V. Proton Pump Inhibitors: Prescribing Practices, Appropriateness of Use, and Cost Incurred in a Tertiary Care, Public, Teaching Hospital in New Delhi, India. MAMC J Med Sci. 2019;5:113-20.
10. Roulet L, Vernaz N, Giostra E, Gasche Y, Desmeules J. Adverse effects of proton pump inhibitors: should we worry about long-term exposure? Rev Med Interne. 2012;33(8):439–45.
11. Scheiman JM, Yeomans ND, Talley NJ, et al. Prevention of ulcers by esomeprazole in at-risk patients using non-selective NSAIDs and COX-2 inhibitors. Am J Gastroenterol. 2006;101(4):701–10.
12. Bargade MB, Mahatme MS, Hiware S, Admane PD. Cost minimization analysis of proton pump inhibitors in India. Int J Basic Clin Pharmacol. 2016;5:1043-7.
13. M ZA, Lavu A, Ansari M, V RA, Vilakkathala R. A Cross-Sectional Study on Single-Day Use of Proton Pump Inhibitors in Tertiary Care Hospitals of South India. Hosp Pharm. 2021;56(2):109-115.
14. Luo H, Fan Q, Xiao S, Chen K. Changes in proton pump inhibitor prescribing trend over the past decade and pharmacists' effect on prescribing practice at a tertiary hospital. BMC Health Serv Res. 2018;18(1):537
15. Kadam P, Tiwari S, Daswani B, Taware A, Hiray R. Pharmacoeconomics and Utilization of Intravenous Proton Pump Inhibitors in a Tertiary Care Hospital. J Pharm Care. 2022;10(3):115-121.
16. Kaplan GG, Bates D, McDonald D, Panaccione R, Romagnuolo J. Inappropriate use of intravenous pantoprazole: extent of the problem and successful solutions. Clin Gastroenterol Hepatol. 2005;3:1207-14
17. Bez C, Perrottet N, Zingg T, Leung Ki E-L, Demartines N, Pannatier A. Stress ulcer prophylaxis in non-critically ill patients: a prospective evaluation of current practice in a general surgery department. J Eval Clin Pract. 2013;19(2):374–8.
18. Shahbazi Khamas S, Darvishi F, Taghvaye-Masoumi H, Rafiei E, Jafari A. The Utilization Evaluation of Intravenous Pantoprazole for Stress Ulcer Prophylaxis in a Major Teaching Hospital. J Pharm Care. 2022;10(3):128-135.
19. Biswas S, Sufian AA, Sarkar PK, et al. Over prescription of proton pump inhibitors on discharge of Medical Inpatients. J Med. 2017;18:27-29.
IssueVol 11, No 2 (Spring 2023) QRcode
SectionOriginal Article(s)
DOI https://doi.org/10.18502/jpc.v11i2.13360
Proton Pump Inhibitors; Prescribing; Rational Use; Drug Safety

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
Juneja S, Rana P, V Manoj S, Kalia R, Pal Singh R. Appropriateness of Proton Pump Inhibitor Use in Hospitalized Patients: A Cross Sectional Study in a Tertiary Care Hospital in North India. J Pharm Care. 2023;11(2):61-65.